Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
100%
Metformin
82%
Warfarin
67%
Dicloxacillin
56%
Normal Human
51%
Paclitaxel
50%
Chemotherapy-Induced Peripheral Neuropathy
48%
CYP3A4
46%
Drug-Drug Interaction
44%
Flucloxacillin
40%
Chemotherapy
38%
CYP2D6
36%
Cohort Study
32%
Drug Metabolism
30%
Non Insulin Dependent Diabetes Mellitus
28%
Clinical Pharmacokinetics
28%
Cytochrome P450
27%
CYP2C19
26%
Neuropathy
26%
P-Glycoprotein
24%
Malignant Neoplasm
23%
Messenger RNA
22%
Biological Marker
20%
CYP2C9
20%
Morphine
19%
Pharmacokinetic Modeling
18%
Adverse Event
18%
Receptor Agonist
18%
Antivitamin K
18%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
18%
Nitric Oxide
18%
Clopidogrel
18%
Neurotoxicity
17%
CYP2C8
17%
Inflammation
16%
Anticoagulant Agent
15%
Receptor
13%
Rosiglitazone
13%
Hemoglobin A1c
13%
Effusion
13%
Pharmacogenetics
11%
Clinical Trial
11%
Placebo
11%
Statin (Protein)
11%
Taxane
11%
Pharmacodynamics
11%
Organic Cation Transporter 1
10%
Rifampicin
10%
Interleukin 6
10%
CYP2B6
10%
Biochemistry, Genetics and Molecular Biology
Pharmacokinetics
64%
Genetic Divergence
35%
Allele
30%
Drug Interaction
21%
Genotyping
21%
Single-Nucleotide Polymorphism
21%
Steady State
20%
Clinical Trial
19%
Induced Pluripotent Stem Cell
18%
Normal Human
16%
HNF1A
13%
Blood Plasma
12%
Pharmacodynamics
11%
Drug Metabolism
10%
Cohort Study
10%
Prevalence
10%
Sensory Neuron
10%
Morphine-3-Glucuronide
10%
Morphine-6-Glucuronide
10%
Pharmacogenetics
10%
Gene Interaction
9%
Insulin Sensitivity
9%
Rosiglitazone
9%
Drug Screening
9%
Proton Pump
9%
Glucuronosyltransferase
9%
Bile Acid
9%
Tumor Spheroid
9%
Twin Study
9%
Gluconeogenesis
9%
Concentration at Steady-State
9%
Renal Clearance
9%
Isoform
9%
Genetic Association
9%
Bone Remodeling
9%
Vitamin K
9%
Light Chain
9%
Neurofilament Light
9%
Blood Level
8%
Messenger RNA
8%
SLCO1B1
7%
Small Molecule
7%
Dizygotic Twins
6%
Serotonin
6%
CYP3A
6%
Clinical Pharmacology
6%
Glucose Utilization
5%
Hepatocyte
5%
CYP3A4
5%
Glucose Metabolism
5%
Medicine and Dentistry
Chemotherapy
27%
Glycon
25%
Breast Cancer
18%
Single Nucleotide Polymorphism
18%
Pharmacokinetics
14%
Hazard Ratio
12%
Clinical Trial
10%
Pharmacogenetics
10%
Premenopause
10%
Polycystic Ovary Syndrome
9%
Side Effect
9%
Chemotherapy-Induced Peripheral Neuropathy
9%
Prevalence
9%
Cohort Analysis
9%
Morphine
9%
Patient with Type 2 Diabetes
9%
In Vitro
9%
Vitamin K Antagonist
9%
Drug Interaction
9%
Bone Remodeling
9%
Neuropathy
9%
Tumor Spheroid
7%
Cumulative Incidence
6%
Placebo
6%
Homozygote
6%
CYP3A4
6%
Maturity Onset Diabetes of the Young
5%
Recurrent Disease
5%
Docetaxel
5%
Metastatic Breast Cancer
5%
